FDA Approves Generic Methotrexate Injection for Multiple Cancer Types

Alembic Pharmaceuticals Limited, a research and development pharmaceutical company based in India, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Methotrexate Injection USP.

This approval provides patients with a new generic option for the folate analog metabolic inhibitor, which is used to treat various cancers and autoimmune conditions such as rheumatoid arthritis and severe psoriasis. The medication will be available in 50 mg/2 mL (25 mg/mL) multi-dose vials and 1g/40 mL (25 mg/mL) single-dose vials.

Main data that support the findings

The FDA granted final approval for this ANDA after determining that the product is therapeutically equivalent to the reference listed drug (RLD). In this case, the reference product is the Methotrexate Injection USP manufactured by Hospira, Inc., available in the same 50 mg/2 mL multi-dose and 1g/40 mL single-dose concentrations.

As a folate analog metabolic inhibitor, methotrexate works by interfering with the metabolic processes of certain cells. For patients with cancer, this means the drug is indicated for several specific neoplastic diseases, including acute lymphoblastic leukemia, meningeal leukemia (used for both prophylaxis and treatment), non-Hodgkin lymphoma, osteosarcoma, breast cancer, squamous cell carcinoma of the head and neck and gestational trophoblastic neoplasia

Beyond its use for patients with cancer, the FDA approval covers the use of this injection for the treatment of three specific inflammatory and autoimmune conditions: rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA) and severe psoriasis.

The receipt of a final approval for an ANDA is a significant regulatory milestone that directly impacts treatment accessibility for patients with cancer and autoimmune diseases. Unlike a New Drug Application, which requires extensive original clinical trials to prove safety and effectiveness, an ANDA allows a manufacturer to demonstrate that its generic version is bioequivalent to a previously approved brand-name drug. This means the generic medication must deliver the same amount of active ingredient into a patient's bloodstream in the same amount of time as the reference listed drug. For those managing long-term conditions like rheumatoid arthritis or osteosarcoma, these approvals are vital because they introduce competition into the pharmaceutical market, which typically leads to lower out-of-pocket costs and a more stable supply of essential medications.

Trial details

The approval of this medication was processed through the FDA’s Abbreviated New Drug Application pathway. This pathway is used for generic medicines, which are required to undergo rigorous review to ensure they perform the same way in the body as the original brand-name drug. By receiving "final approval," the Alembic Pharmaceuticals version of methotrexate injection has met the federal standards for therapeutic equivalence to the Hospira reference drug.

This specific approval adds to the manufacturer's portfolio of authorized medications. Alembic Pharmaceuticals currently holds a cumulative total of 236 ANDA approvals from the FDA, which includes 218 final approvals and 18 tentative approvals. The company, which has been operating since 1907, utilizes research and manufacturing facilities that are approved by regulatory authorities in several developed countries, including the United States.

Safety

The use of methotrexate injection must be conducted according to the detailed indications provided on the product label. As a folate analog metabolic inhibitor, the medication's safety profile is managed through specific dosing and administration guidelines tailored to the condition being treated, whether it is a neoplastic disease like breast cancer or an inflammatory condition like rheumatoid arthritis.

Patients and caregivers should refer to the full prescribing information for detailed safety data regarding the 50 mg/2 mL and 1g/40 mL vials. Because the 50 mg/2 mL version is a multi-dose vial and the 1g/40 mL version is a single-dose vial, healthcare providers must follow the appropriate protocols for each format to ensure patient safety. The label provides comprehensive details on the indications and usage for each of the ten approved conditions, ranging from pediatric treatments for polyarticular juvenile idiopathic arthritis to adult treatments for squamous cell carcinoma.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

Reference:

“Alembic Pharmaceuticals Limited announces USFDA Final Approval for Methotrexate Injection USP, 50 mg/2 mL (25 mg/mL) Multi-Dose Vials & 1g/40 mL (25 mg/mL) Single-Dose Vials,” news release.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.